Top Biotech Stocks for 2011 and January Catalyst Event Dates

Stocks Mentioned:  Dendreon, Human Genome Sciences, Eli Lilly, Cerus, Curis, Compugen, Spectrum Pharmaceuticals, Impax Laboratories, Exelixis, Medivation, Seattle Genetics, Corcept, PolyMedix, BioMarin, Endo Pharmaceuticals, DepoMed, Mannkind, Orexigen Therapeutics, AstraZeneca, Clinical Data

Here are the Top Biotech Picks for 2011, Stocks Highlighted at the JP Morgan Healthcare Conference, News on Human Genome Sciences, Dendreon, Bargain Biotech Stocks, and January FDA Catalysts.

5 Bargain Biotech Stocks for 2011
Street Picks

NEW YORK (InvestorPlace) -- On July 8, 2009, I recommended five cutting-edge medical products and biotech stocks. Even factoring in the single dud of the group, you would still have an average return of more than 110%.

Do I have your attention? Good, because I've put together a list of the hottest bargain biotech stocks to buy for 2011. Some of the names will look familiar because I think the stocks still have legs, while others have been swapped out for new names that I think have more potential in the year ahead.

Here are the best biotech stocks to own now:
Continued

Compugen, The Future of Drug Discovery

Here is some really good analysis on the Future of Drug Discovery. Computerized Genetic Analysis for targeted therapeutics using Comugen's technology. It is a very complex system that doesn't have a guarantee for success but it is changing the way pharmaceutical and biotech companies research innovative new drugs. Currently, Zacks has a #1 Strong Buy Ranking on Compugen (CGEN).  Visit their website at www.cgen.com.


Compugen collaborates with many companies and is poised for a breakout with a future blockbuster drug discovery, which would give them royalty payments for their innovation. Find out more about Compugen's collaborative partners here, some notable companies include Pfizer, Roche, Teva, and Merck.

Compugen Licenses Novel Oncology Target to Seattle Genetics

Agreement provides Seattle Genetics with research license and option for exclusive commercial license to monoclonal antibody-based therapeutics targeting Compugen-discovered target

Existence of target initially predicted in silico using Compugen’s Monoclonal Antibody Targets Discovery Platform

Seattle Genetics Announces Pivotal Results in Lymphoma Drug Trial

Image via WikipediaLymphoma news from Seattle Genetics hitting the web. This company is really making strides with Non-Hodgkin's Lymphoma drug Brentuximab. This drug is partnered with Takeda Oncology's Millennium. Takeda is a global pharmaceutical firm who specializes in Clinical Trials and marketing on a global scale. Brentuximab elicited 75% response rate in patients that had already rejected other cancer drugs, which is common.

Seattle Genetics Reports Disappointing Phase II Data For AML, and Upcoming Clinical Trial Results for NHL

Wikinvest-Seattle Genetics (SGEN)

Disappointing news reported from Seattle Genetics today. I actually like the stock after the price bottoms out as they are focusing their efforts on Non-Hodgkins Lymphoma drug, brentuximab.  Wait for the massive sell-off in the next week or two and wait for Clinical Trials results to come out in about 6 weeks from Phase II testing for NHL.  I anticipate a massive sell-off in the next couple of days after todays disappointing clinical trials news on a separate medication for AML, acute myeloid leukemia.

KEYWORDS: Antibody-Drug Conjugates, Millenium Pharmaceuticals, Seattle Genetics, AML, Monoclonal Antibody Therapeutics, Hodgkin Lymphoma

Seattle Genetics is ditching further development of its clinical-stage acute myeloid leukemia (AML) candidate lintuzumab (SGN-33) after a Phase IIb trial failed to show the drug extended overall survival. The firm says it will now focus on the rest of its clinical pipeline, headed by the Phase III-stage Hodgkin lymphoma drug, brentuximab vedotin, which is being developed in collaboration with Millennium Pharmaceuticals.

Ariad and Cyclacel To Start Clinical Trials for Blood Cancer Drugs for Leukemia

Image via Wikipedia From The Street's Adam Feuerstein

Ariad, Cyclacel To Start Key Drug Trials


Stock quotes in this article:ARIA, CYCC, SGEN, NVS, BMY